Benzinga | Mar 3, 2021 06:56AM EST

Asensus Surgical Announces FDA Clearance For Senhance Surgical System

Indications Expand to Include New Procedures in Large General Surgery Market

Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (NYSE:TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery(tm), today announced the Company has received an additional FDA clearance for the Senhance Surgical System which allows for indication expansion in general surgery in the United States.

Asensus Surgical's technology platform, Senhance(r) Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform).

"The expansion into general surgery for the Senhance Surgical System is a major milestone for the growth and clinical applicability of our technology," said Anthony Fernando, Asensus Surgical President and CEO. "General surgery is, by far, the largest area of manual laparoscopy which can benefit from the precision and insight of Performance-Guided Surgery. The indication expansion allows Senhance to be used in many high-value, complex reconstructive surgeries such as those used to treat reflux and obesity. Including previous indications granted, the Senhance Surgical System can now be utilized in over 2.7 million general surgical procedures performed in the US annually."

"Many of the procedures we perform in general surgery require complex reconstruction throughout a wide surgical field," said Dr. Sabino Zani, Assistant Professor of Surgery at Duke University and an investigator in the clinical studies submitted for indication expansion. "Senhance can now be seen as a widely applicable tool for general surgeons across the broad range of procedures that may be performed from deep in the pelvis to the upper abdomen."